2023 eXCELL Biotech Received a Japan Patent for the method to manufacture xenogeneic urothelial cells and the theraputic use of intravesical administration of xenogeneic urothelial cells to treat bladder cancer and cystitis.

The Japan Patent Office has granted a patent (Patent No. 7272676) for our intravesical xenogeneic urothelial cell therapy for bladder cancer and cystitis.
The patent relates to the invention of the method to manufacture xenogeneic urothelial cells and the theraputic use of intravesical administration of xenogeneic urothelial cells to treat bladder cancer and cystitis.